Browse Category

NASDAQ:ROIV News 11 December 2025

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

December 11, 2025 – Roivant Sciences Ltd. (Nasdaq: ROIV) has just given Wall Street a dense dose of biotech optimism. Here’s what today’s Investor Day and the latest data mean for the stock. ROIV stock today: rally near 52‑week highs Roivant shares traded around the low‑$20s on December 11, with intraday prices near $21.5 according to real‑time market data. That move builds on a powerful run: The immediate catalyst for today’s jump: Roivant’s 2025 Investor Day, where management laid out an aggressive roadmap of 3+ potential product launches, 4+ expected NDA/BLA filings, and 8+ pivotal readouts over the next three

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop